Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCirata Regulatory News (CRTA)

Share Price Information for Cirata (CRTA)

Share Price is delayed by 15 minutes
Get Live Data
16.20    -0.70 (-3.99%)
Bid:
15.75
Ask:
17.90
Spread: 2.15 (13.651%)
Market Cap: £20.48m
CRTA Live PriceLast checked at - London Stock Exchange

Intraday Cirata Share Chart

Board Appointments

1 Oct 2024 07:00

RNS Number : 3208G
Cirata PLC
01 October 2024
 

1 October 2024

 

Cirata plc

("Cirata" or the "Company")

Board Appointments

 

 

Cirata (LSE: CRTA), is pleased to announce that Amanda Jobbins and Eric Collins have been appointed as NonExecutive Directors with immediate effect.

 

Mr Peter Lees, Senior Independent Director (SID) who joined the board 9 August 2022, and chairs the Nomination Committee, will resign from his position effective 31 December 2024.

 

Amanda brings with her a wealth of international experience, having served as Global Chief Marketing Officer for major SaaS and IT enterprise software companies in the USA, Europe and Asia. Amanda currently serves as Global Chief Marketing Officer for Vodafone Business and Director of GTM & Strategic Partners. Prior to this, she was Global Chief Marketing Officer at Infor as well as Chief Marketing Officer and Senior Vice President of Global Business Development at Oracle.

 

Eric is a seasoned entrepreneur and business builder in addition to being the co-founder of Impact X Capital Partners: a venture capital firm founded to back underrepresented entrepreneurs across Europe and the USA, in sectors such as technology, healthcare, education and media.

 

Eric served as Chief Operating Officer of Digital Surgery, acquired by Medtronic in 2020, which is a global leader in healthcare technology. Prior to this, Eric served as Chief Revenue and Distribution Officer at SwiftKey, a virtual keyboard app that was acquired by Microsoft in 2016, where he was responsible for driving both user and revenue growth.

 

Ken Lever, Chair, commented:

 

"Amanda and Eric bring broad business experience across a range of sectors to our board. Amanda has an excellent track record across major enterprise software businesses that will help Cirata capitalise on its potential through investment in sales, marketing and products. Eric's business acumen and proven ability as a revenue builder and value creator will be invaluable as we look to deliver on our growth strategy and meet our medium-term ambitions. We are delighted to have both on board.

 

During this period of major change and transition for Cirata Peter Lees' guidance and advice has been invaluable. The board extends its sincere thanks for the contribution Peter has made and wishes him well for the future."

 

Regulatory disclosure The following disclosures are made in accordance with Schedule 2(g) of the AIM Rules for Companies:

 

 

 

Amanda Catherine St Levans Jobbins, aged 56, holds no ordinary shares or options in the Company. Amanda's current and previous directorships are as follows:

 

 

Current Directorships/Partnerships

Previous Directorships/Partnerships (last 5 years)

The Cabin Gym Limited

Dowding Levans Capital Limited

Dabco Limited

Cable & Wireless Trade Mark Management Limited

Hang Technologies Limited

 

 

 

Eric Davis Collins, aged 58, holds no ordinary shares or options in the Company. Eric's current and previous directorships are as follows:

 

 

Current Directorships/Partnerships

Previous Directorships/Partnerships (last 5 years)

Impact X Capital Partners LLP

Impact X Launch LLP

IXC I (Scotland) Ltd

IXC I (England) Ltd

IXC I FP LP

Impact X Operations LLP

Impact X Studios Limited

The Foundation for Social Entrepreneurs

Autograph ABP

Looted LLP

 

Tech Nation Group Limited

 

 

 

Save for the disclosures above, there are no further disclosures to be made in accordance with Rule 17 and Schedule 2(g) of the AIM Rules.

 

 

For further information, please contact: 

 

Cirata

+1 (925) 380 1728

Stephen Kelly, Chief Executive Officer

Ijoma Maluza, Chief Financial Officer

Daniel Hayes, Investor Relations

FTI Consulting

+44 (0)20 3727 1137

Matt Dixon / Kwaku Aning / Usama Ali

Stifel (Nomad and Joint Broker)

+44 (0)20 7710 7600

Fred Walsh / Ben Good / Sarah Wong

Panmure Liberum (Joint Broker)

+44 (0)20 3100 2000

Max Jones / John More

 

 

About Cirata

 

Cirata, accelerates data-driven revenue growth by automating data transfer and integration to modern cloud analytics and AI platforms without downtime or disruption. With Cirata, data leaders can leverage the power of AI and analytics across their entire enterprise data estate to freely choose analytics technologies, avoid vendor, platform, or cloud lock-in while making AI and analytics faster, cheaper, and more flexible. Cirata's portfolio of products and technology solutions make strategic adoption of modern data analytics efficient and automated. For more information about Cirata, visit www.cirata.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAEAKNEDEKLEFA
Date   Source Headline
1st Nov 20247:00 amRNSGrant of Share Options to PDMRs
24th Oct 20247:00 amRNSPDMR Transactions
9th Oct 20247:00 amRNSQ3 Trading Update and Outlook
2nd Oct 20243:19 pmRNSAmendment of OEM sales partnership with IBM
1st Oct 20247:00 amRNSBoard Appointments
30th Sep 20247:00 amRNSHCSC Contract Renewal
25th Sep 20247:00 amRNSAppointment of Interim CFO
19th Sep 202410:30 amRNSHolding(s) in Company
19th Sep 202410:30 amRNSHolding(s) in Company
4th Sep 20247:00 amRNSInterim results
31st Jul 20245:44 pmRNSHolding(s) in Company
31st Jul 20242:35 pmRNSDirector/PDMR Shareholding
26th Jul 20241:51 pmRNSHolding(s) in Company
19th Jul 20245:54 pmRNSDelay of Admission
17th Jul 20247:00 amRNSResult of Fundraising
16th Jul 20244:47 pmRNSPrimaryBid Offer
16th Jul 20244:46 pmRNSLaunch of Fundraise
16th Jul 20244:45 pmRNSQ2 Trading Update and Outlook
28th Jun 20248:00 amRNSBlock Listing Return
25th Jun 20247:08 amRNSGM Launches Phase 2
19th Jun 20247:00 amRNSTotal Voting Rights
21st May 20247:00 amRNSOPPO Contract Renewal
14th May 20243:28 pmRNSResult of Annual General Meeting
29th Apr 20245:01 pmRNSFurther re: Annual Report & Notice of AGM
24th Apr 20247:00 amRNSDirectorate Change
17th Apr 20243:05 pmRNSAnnual Report & Notice of AGM
9th Apr 20247:00 amRNSQ1 FY24 Trading Update
4th Apr 20247:00 amRNSFinal Results
6th Mar 20245:19 pmRNSHolding(s) in Company
4th Mar 20242:53 pmRNSHolding(s) in Company
21st Feb 20241:27 pmRNSHolding(s) in Company
15th Feb 20244:27 pmRNSDirector/PDMR Shareholding
15th Feb 20247:00 amRNSChair appointment
9th Jan 20247:00 amRNSTrading Update
4th Jan 20243:10 pmRNSTotal Voting Rights
4th Jan 20242:41 pmRNSHolding(s) in Company
3rd Jan 20245:40 pmRNSHolding(s) in Company
2nd Jan 20249:32 amRNSNotice of Q4 FY23 Trading Update
14th Dec 20236:12 pmRNSBlock Listing Application
12th Dec 20235:32 pmRNSGrant of Share Options to PDMRs
12th Dec 20238:29 amRNSHolding(s) in Company
7th Dec 20237:00 amRNSDirector/PDMR Shareholding
6th Dec 20237:00 amRNSTotal Voting Rights
5th Dec 202310:25 amRNSHolding(s) in Company
24th Nov 20235:40 pmRNSDirector/PDMR Shareholding
23rd Nov 202310:08 amRNSHolding(s) in Company
21st Nov 20235:41 pmRNSHolding(s) in Company
21st Nov 20231:28 pmRNSHolding(s) in Company
21st Nov 20237:00 amRNSDirector/PDMR Shareholding
17th Nov 20235:54 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.